Safety evaluation of intravitreal administration of VEGF trap in cynomolgus monkeys for 13 weeks.
Investigative Ophthalmology & Visual Science, 47(13), pp.1751-1751.
Eylea
Pharmacokinetics and ocular tissue penetration of VEGF Trap after intravitreal injections in rabbits
Investigative Ophthalmology & Visual Science, 47(13), pp.1430-1430.
Prevention of experimental choroidal neovascularization and resolution of active lesions by VEGF trap in nonhuman primates
Arch Ophthalmol. 2011 Aug;129(8):1042-52. doi: 10.1001/archophthalmol.2011.210.
ABSTRACT
OBJECTIVE: To evaluate the efficacy of systemic and intravitreous administration of VEGF Trap (aflibercept) in a nonhuman primate model of choroidal neovascularization (CNV).
Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration
Ophthalmic Surg Lasers Imaging Retina. 2014 Sep-Oct;45(5):394-7. doi: 10.3928/23258160-20140909-03.
ABSTRACT
BACKGROUND AND OBJECTIVE: This study examines the clinical response of patients transitioned to aflibercept, the newest anti-VEGF medication, due to persistent evidence of exudation on optical coherence tomography (OCT) despite regular treatment with bevacizumab and/or ranibizumab.